2026-10-25
Does not pass
Cellebrite DI does not pass the ethical screen. The binding factor is interest/revenue 5.0%.
NAS100 28,437 +0.91%
S&P 7,689 +1.58%
GOLD $4,070 +3.28%
BTC $80,381 +3.93%
VIX 16.61 −20.26%
latest tape · as of 23:21 UTC · 4 Nov
The Screen · Technology · Software - Infrastructure
Cellebrite DI Ltd.
CLBT · Nasdaq · USD · Market cap $3.0B · 1,285 employees
Cellebrite DI Ltd.
FAIL · Does not pass the screen12.25 USD
Price as of 3 Nov 2026Daily close, not a live quote
Screened 2026-11-03 · the tape above runs as of 23:21 UTC · 4 Nov · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price12.25 USD at the 3 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 3 Nov 2026
- Our regime readAccumulation, as of 3 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.04)
- Last reviewed3 Nov 2026 (2 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $12.74 to $21.23, base estimate $15.99 (screen dated 2026-11-03).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.04, read 2026-10-30
- Ethical does not pass the values gate
Price12.25 USD
Fair value15.99
Ethical score94.7/100
Value readUndervaluedas of 3 Nov 2026
Our investment reviews on this name
2026-10-25Read Accumulation11.38+7.6% to today ✓Markdown gives way to Accumulation
2026-10-18Read Markdown11.38+7.6% to today Accumulation gives way to Markdown first Markdown read since October
2026-10-11Read Accumulation11.50+6.5% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown11.50+6.5% to today Distribution gives way to Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its accumulation label.
Cellebrite DI Ltd. holds its Accumulation at $12.25. The statistical read favours the sellers, held for 35 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the sellers, held for 35 days |
| Price at the screen | $12.25 |
| Valuation | 51.87 trailing · 18.26 forward price to earnings |
| Values screen | FAIL · score 94.7 |
| Beta | 1.13 |
Five Screens, Shown in Full
Does not pass. Interest/revenue 5.0%
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 0.69% | Below 33% | Interest-bearing debt is just 0.7% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 13.35% | Below 33% | Cash held in interest-bearing accounts and securities is 13.4% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 5.03% | Below 5% | 5.0% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Cellebrite DI does not pass the ethical screen. The binding factor is interest/revenue 5.0%.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Cellebrite DI clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
Follow this verdict
Get an email when CLBT's ethical verdict changes
Today CLBT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Conscience flag · AFSC Investigate, Don’t Buy Into Occupation
What the Numbers Say It Is Worth
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Documented on AFSC Investigate / Don’t Buy Into Occupation — category: Corporate Complicity Report / Annex 2 Company List. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 3 Nov 2026: it trades at roughly a 23% discount to our $15.99 fair value, moderate competitive moat, 15.80% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. A 23.4% discount to the base estimate.
Third-party analyst targets: 7 covering, consensus Strong Buy. The average target sits +22% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $15.99, with a range of $12.74 to $21.23, dated to the 2026-11-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsCellebrite Turns Seized Phones Into Courtroom Evidence
Every time police in London or Tel Aviv pull a locked phone from a suspect, someone has to turn that data into usable evidence without breaking the law. Cellebrite builds the tools that do exactly that, moving bits from devices into review platforms that investigators actually trust. The business sits in a narrow lane where demand keeps rising as crimes move online.
Revenue is growing 19 percent, margins sit at 14 percent and return on equity reaches 16 percent, all while the shares trade at 23.4 times forward earnings against a fair-value estimate 20 percent higher. A moderate moat and a clean ethical screen support the case for steady compounding rather than explosive growth. Analyst targets cluster around 20 dollars, which lines up with the current pricing leaving limited room for error.
Israel-based operations bring currency and geopolitical risk that can swing results quickly, and competition from bigger software names could cap pricing power over time. The moderate moat means any slowdown in law-enforcement budgets would hit harder than the numbers currently suggest.
Analysis, not advice.
| Forward P/E | 18.3xfairly priced for its growth rate |
| Trailing P/E | 51.9xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 0.23 |
| EPS, forward | 0.65 |
| Revenue growth | +15.8%steady growth |
| Profit margin | 11.4%thin but positive margins |
| Return on equity | 12.4%a solid return on shareholder capital |
| FCF yield | 4.17% |
| Debt to equity | 4.32heavy leverage: higher risk if revenue softens |
| Current ratio | 1.62healthy short-term liquidity |
| Beta | 1.13moves a little more than the market |
| Short interest, float | 0.06% |
| 52-week range | 9.58 - 19.98 |
| Moat | MODERATE |
| Market cap | $3.0B |
| Employees | 1,285 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Israel and to currency swings; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCLBT trades on Nasdaq (the company is based in Israel). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-01
Accumulation $12.15
+6.8% Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21.
2026-10-25
Accumulation · changed $11.38
+0.0% Entry 9
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21.
2026-10-18
Markdown · changed $11.38
-1.0% Entry 8
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21.
2026-10-11
Accumulation · changed $11.50
+0.0% Entry 7
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21.
2026-10-02
Markdown · changed $11.50
+4.5% Entry 6
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21.
2026-08-25
Distribution · changed $11.00
-28.8% Entry 5
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 28.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21.
2026-07-24
Markup $15.44
+11.8% Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.8% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21.
2026-07-18
Markup $13.81
+0.0% Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (6 analysts) rates it strong buy, with a mean price target of $21.
2026-07-03
Markup $13.81
+0.0% Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (95). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02
Markup $13.81
Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (95). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Cybersecurity Stocks To Watch After The Binance Theft Shock Yahoo Finance · 6d ago
- October 2026 Crypto Stocks To Watch Yahoo Finance · 14d ago
- Genesis Momentum Powers Cellebrite's Autumn Release: More Evidence, Deeper Insight, Broader Access for Investigations Yahoo Finance · 14d ago
- Cellebrite to Report Third-Quarter 2026 Financial Results on November 12, 2026 Yahoo Finance · 15d ago
- 3 Software Stocks Turning AI Into Recurring Revenue Growth Yahoo Finance · 19d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
NTCTNetScout Systems, Inc.
STNEStoneCo Ltd.
FIVNFive9, Inc.
TDCTeradata Corporation
PAGSPagSeguro Digital Ltd.
FOURShift4 Payments, Inc.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-18 | JEWELL MARCUS H | Officer | 12,658 | $161,657 | |
| 2026-05-12 | RAMJI SHIVEN | Officer | 423,550 | · | |
| 2026-05-12 | GEE DAVID NICHOLAS | Officer | 228 | $2,966 | |
| 2026-05-12 | JEWELL MARCUS H | Officer | 383 | $4,983 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $13.05 | +0.1% | · | $1,001 | +0.1% |
| 2 months | $11.03 | +18.5% | · | $1,185 | +18.5% |
| 3 months | $14.53 | -10.1% | · | $899 | -10.1% |
| 6 months | $19.06 | -31.5% | · | $686 | -31.5% |
| 1 year | $16.27 | -19.7% | · | $803 | -19.7% |
| 2 years | $11.67 | +12.0% | · | $1,120 | +12.0% |
| 3 years | $6.15 | +112.4% | · | $2,124 | +112.4% |
| 5 years | $9.91 | +31.8% | · | $1,318 | +31.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CLBT does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.